Lauren Alani, Director of Digital Innovation at Seuss+, on the structural gap between regulator authority and vendor commercial accountability, and how sponsors close it.
The data behind this perspective
- EMA GCP Inspectors Working Group Annual Report 2023 · computer systems generated 46 inspection findings: 5 critical, 22 major. Sponsors received the highest number of critical findings in all three top areas
- Govzilla 2014-2018 analysis · roughly 50% of all global drug FDA Form 483s cite data integrity concerns; 79% of global drug warning letters reference data integrity issues
- FDA Form 483 analysis 2023 · across 1,983 observations, Subparts J, F, and I (records, production controls, laboratory controls) constitute 53.8% of all observations
- ~20% likelihood · estimated chance of receiving an FDA Form 483 at inspection (FDA reference data)
- MHRA GxP Data Integrity Guide · “the organisation needs to take responsibility for the systems used and the data they generate”; data governance must be endorsed at the highest organisational level
“ICH GCP E6(R3) didn’t ask vendors to raise their standards. It asked sponsors to verify that they had.”
Lauren Alani
Regulators write to sponsors. They send inspection notices to sponsors. They ask sponsors for documentation. They publish guidance addressed to sponsors. The vendor ecosystem (eCOA, ePRO, EDC, eTMF, IRT, wearables, AI tools, real-world data platforms) sits one layer down. Vendors operate within whatever specifications a sponsor sets, but they are not directly accountable to the regulator for the trial’s compliance posture.
This is a structural fact. It is not an accident or an oversight in the regulatory framework. It is the design. The regulator’s enforcement reach is the sponsor; the sponsor’s contractual reach is the vendor; the vendor’s reach is the system it builds. In a clean line of accountability, that chain works. In practice, it leaks. The leak is what I call the regulator-vendor gap, and it is structural.
What “the gap” actually looks like
The regulatory framework, particularly ICH GCP E6(R3), EMA’s reflection paper on computerised systems, and FDA 21 CFR Part 11, articulates expectations the sponsor must meet around data integrity, system validation, audit trail, and electronic records. These expectations are written for the sponsor. They are not written for the vendor.
The vendor’s market response is to claim alignment. “Our platform is 21 CFR Part 11 compliant.” “Our validation package supports GCP.” “We follow ALCOA+ principles.” These statements are commercial claims. They may also be entirely accurate. What they are not is the sponsor’s evidence. They are inputs to it.
The danger of that assumption is that sponsors treat vendor compliance claims as if they were sponsor compliance evidence. They are not. Inspectors do not ask the vendor; they ask the sponsor. The sponsor has to produce records that demonstrate the vendor’s claims have been verified, configured to fit the specific trial, and integrated into a data lifecycle the sponsor can defend.
Why the gap exists
It is tempting to read this as a regulatory failure: surely vendors should be directly accountable to regulators? In practice, it would be unworkable. Vendors serve many sponsors, across many regulatory jurisdictions, building many configurations. A regulator cannot oversee every commercial product configuration in every trial. The sponsor is the right unit of regulatory enforcement because the sponsor is the entity that owns the trial, owns the protocol, owns the asset under development, and is the legal person under regulatory duty.
The gap is therefore a feature of the framework, not a bug in it. The framework relies on the sponsor to translate regulatory expectations into vendor specifications, to verify the vendor’s response, and to hold the resulting records for inspection. When that translation work is done well, the chain of accountability holds. When it is delegated to vendors and CROs without sponsor-level evidence, the chain leaks.
How sponsors absorb the gap by default
Sponsors absorb the gap whether or not they recognise it. There are three common patterns I see across clinical-stage biotechs and small to mid-cap pharma.
Pattern 1: Vendor-led specifications
The sponsor selects a vendor, runs through the vendor’s standard discovery process, and accepts the vendor’s standard configuration. The vendor’s framework becomes the trial’s de facto specification. This is fast and feels efficient. It also means the sponsor’s regulatory expectations were never explicitly translated into the trial’s specifications. The translation step (regulatory → vendor-facing requirements) was skipped. When inspectors later ask “show me how your trial-specific requirements were derived from regulatory expectations and verified,” there is no document.
Pattern 2: Trust-by-tier
The sponsor selects a Tier 1 vendor or a Tier 1 CRO and treats the brand as substitute evidence. The thinking goes: a Tier 1 has been audited many times, must therefore be compliant, therefore the sponsor’s compliance burden is reduced. Inspectors do not buy this reasoning. They ask the same questions of every sponsor, regardless of who the vendors are. The Tier 1 brand is a useful input; it is not a discharge of accountability.
Pattern 3: Compliance by certification
The sponsor accepts vendor certifications (ISO 27001, SOC 2, the vendor’s own validation package) as proof of compliance. Certifications are evidence of process maturity. They are not evidence that the specific trial’s data integrity requirements have been met. SOC 2 does not validate that a sponsor’s eCOA configuration captures the right data points in the right format. ISO 27001 does not validate that an EDC system enforces the protocol’s edit checks. These are sponsor-specific verification questions; certifications are a generic backdrop.
Closing the gap
The work of closing the regulator-vendor gap is sponsor-side translation, executed in sequence, with the output captured in sponsor-held records.
Step one is to articulate, in sponsor-owned documentation, what each regulatory expectation requires of this specific trial. Not what it requires of vendors generically; what it requires of this sponsor’s this trial. The output is a set of trial-level regulatory requirements, sponsor-authored, sponsor-signed.
Step two is to translate those regulatory requirements into vendor-facing specifications. The translation is sponsor work. It produces user requirement specifications, configuration documents, and validation acceptance criteria that the vendor will then deliver against. The sponsor sets the bar; the vendor meets the bar; the sponsor verifies that the bar was met. The translation document, signed by the sponsor, is the bridge across the gap.
Step three is verification. The vendor produces validation outputs, configuration evidence, and operational artefacts. The sponsor reviews them against the trial-level specifications. Acceptance is documented in sponsor-held records. Where the vendor’s output falls short, the sponsor escalates and resolves. Where it meets specification, the sponsor accepts in writing. This document trail is what closes the regulator-vendor gap from the sponsor side.
Why this matters now
ICH GCP E6(R3) raised the bar on sponsor oversight expectations in 2023, with progressive enforcement through 2026. EMA’s guidance on computerised systems is increasingly specific. FDA inspections of clinical-stage assets are increasingly attentive to electronic records and audit trails. The structural gap was always there. The regulatory attention to whether sponsors have closed it is intensifying.
Sponsors who continue to absorb the gap by default are not exposed catastrophically; they are exposed cumulatively. Findings are usually moderate. Patterns of findings are not. An accumulation of “sponsor failed to demonstrate oversight” observations across trials, sites, or programmes shows up as a quality system weakness, and that observation can drag valuation, partnership terms, and submission timing.
The closing question
Look at one of your active trials. Find the document that translates the trial’s regulatory expectations into vendor-facing specifications, in your own organisation’s voice, signed by your own quality leadership. If that document does not exist, it is the gap. The work is to author it before someone else asks why it was missing.
Continue reading: Requirements Before Selection for the procurement-stage discipline that prevents the gap from forming in the first place. Accountability Cannot Be Delegated for the underlying principle. All four perspectives in the insights archive. About Lauren for the working method.
Frequently asked
Why don’t regulators just hold vendors directly accountable?
The regulatory framework is built around the sponsor as the unit of enforcement because the sponsor owns the trial, the protocol, the asset, and the legal duty. Vendors serve many sponsors across many jurisdictions, with many configurations, which would be unworkable to oversee directly. The framework relies on sponsors to translate regulator expectations into vendor specifications and to verify compliance.
Are vendor compliance claims (Part 11, GCP, ISO) ever sufficient for inspection?
They are useful inputs but not sufficient as sponsor evidence. Inspectors ask for sponsor records that demonstrate verification of vendor claims in the context of the specific trial. A vendor’s generic compliance posture has to be re-expressed as auditable evidence in the sponsor’s records, mapped to the sponsor’s trial-level requirements.
What is the minimum sponsor-side documentation that closes the gap?
At minimum: a trial-level regulatory requirements document (sponsor-authored), a translated user requirements specification or configuration document, a validation acceptance plan, evidence of vendor delivery against that plan, sponsor-signed acceptance, and a periodic oversight review record. Form varies; principles are: sponsor-authored, sponsor-signed, contemporaneous, and held in the sponsor’s quality system.
How does ICH GCP E6(R3) change the regulator-vendor gap calculus?
E6(R3) raised explicit expectations around sponsor oversight of computerised systems and delegated parties, with quality-by-design framing. Sponsors that previously relied on vendor and CRO assurances have a higher bar now to demonstrate active, documented oversight. The structural gap is the same; the regulatory attention to how sponsors are closing it has increased.
Does this principle apply to small biotechs the same way as large pharma?
Yes, with proportionality. The principle is identical. The execution scales: a small biotech can use lighter-weight documentation, fewer SOPs, and a smaller quality system, but the sponsor-side translation and verification must still happen. The size of the sponsor does not change the regulatory framework’s expectations of the sponsor.
